Geode Capital Management LLC Sells 29,708 Shares of Moderna, Inc. $MRNA

Geode Capital Management LLC lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,219,644 shares of the company’s stock after selling 29,708 shares during the quarter. Geode Capital Management LLC’s holdings in Moderna were worth $271,415,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Douglas Lane & Associates LLC lifted its position in shares of Moderna by 14.4% during the 4th quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock worth $38,085,000 after buying an additional 163,031 shares during the period. Banco Santander S.A. lifted its position in shares of Moderna by 22.1% during the 3rd quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after buying an additional 39,056 shares during the period. Sigma Planning Corp bought a new position in shares of Moderna during the 4th quarter worth approximately $907,000. Gateway Investment Advisers LLC lifted its position in shares of Moderna by 1,445.1% during the 4th quarter. Gateway Investment Advisers LLC now owns 140,454 shares of the company’s stock worth $4,142,000 after buying an additional 131,364 shares during the period. Finally, Telemark Asset Management LLC bought a new position in shares of Moderna during the 3rd quarter worth approximately $12,915,000. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Friday, May 15th. The stock was sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the completion of the sale, the president directly owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 68,281 shares of company stock valued at $3,280,293 over the last three months. Company insiders own 10.80% of the company’s stock.

Moderna Stock Down 2.4%

Shares of Moderna stock opened at $46.06 on Tuesday. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The business has a fifty day simple moving average of $50.11 and a 200 day simple moving average of $42.66. The stock has a market cap of $18.28 billion, a PE ratio of -5.65 and a beta of 1.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same period last year, the firm earned ($2.52) earnings per share. The firm’s revenue for the quarter was up 260.2% on a year-over-year basis. Research analysts predict that Moderna, Inc. will post -6.49 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Piper Sandler raised their target price on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, February 23rd. Jefferies Financial Group set a $37.00 target price on Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Evercore set a $35.00 target price on Moderna in a research report on Tuesday, February 17th. The Goldman Sachs Group raised their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Finally, Barclays raised their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $35.73.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna announced an expanded collaboration with CEPI to develop a potential vaccine against Bundibugyo ebolavirus, with CEPI committing up to $50 million to fund preclinical work and Phase 1 testing. The external funding reduces development risk and highlights continued interest in Moderna’s mRNA platform. Article Title
• Positive Sentiment: Moderna and Merck presented 5-year data showing intismeran autogene plus KEYTRUDA cut the risk of recurrence or death in high-risk melanoma patients, reinforcing the company’s oncology pipeline and keeping investor attention on a possible future commercial opportunity. Article Title
• Neutral Sentiment: Additional coverage echoed the CEPI Ebola partnership and the melanoma data, but did not add materially new information beyond the original announcements. Article Title
• Neutral Sentiment: Several articles discussed broader interest in mRNA-based personalized cancer vaccines and the relevance of Moderna’s technology, which may be supportive long term but is not an immediate financial catalyst. Article Title
• Negative Sentiment: Investors may still be cautious because these are early-stage vaccine and cancer programs, so the news improves sentiment but does not yet change Moderna’s earnings outlook in the near term.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.